08:59 IST
NSE
Board Meeting Outcome
Cohance Lifesciences Board Meeting Outcome
Cohance Lifesciences approved the appointment of Mr. Umang Vohra as Chairman and Group CEO, succeeding Mr. Vivek Sharma who resigned effective April 30, 2026. The Board also approved the 'Cohance Lifesciences Limited – Employee Stock Option Plan, 2026' covering 2.59 crore options. These leadership transitions and incentive plans are subject to shareholder approval via postal ballot.